Bicycle Therapeutics, ThromboGenics advance study of DME treatment

Bicycle Therapeutics has received a milestone payment in connection with initiation of a clinical study evaluating THR-149 for the treatment of diabetic macular edema.

The phase 1 open-label, multicenter, dose escalation study will proceed under the biotechnology company’s ophthalmology alliance with the biopharmaceutical company ThromboGenics.

The two companies are expanding their collaboration to further identify and optimize bicyclic peptide products for treating ophthalmic diseases, according to a press release from Bicycle Therapeutics.

THR-149 is a plasma kallikrein inhibitor that is being developed with the Bicycle bicyclic peptide platform and is intended for intravitreal administration. The trial will evaluate the safety of the treatment, and results are anticipated by mid-2019, according to the release.

Bicycle Therapeutics has received a milestone payment in connection with initiation of a clinical study evaluating THR-149 for the treatment of diabetic macular edema.

The phase 1 open-label, multicenter, dose escalation study will proceed under the biotechnology company’s ophthalmology alliance with the biopharmaceutical company ThromboGenics.

The two companies are expanding their collaboration to further identify and optimize bicyclic peptide products for treating ophthalmic diseases, according to a press release from Bicycle Therapeutics.

THR-149 is a plasma kallikrein inhibitor that is being developed with the Bicycle bicyclic peptide platform and is intended for intravitreal administration. The trial will evaluate the safety of the treatment, and results are anticipated by mid-2019, according to the release.